CardiAQ Closes $6.5 Million ‘Series A’ Funding for Its Novel Transcatheter Mitral Valve Implantation (TMVI) System

WINCHESTER, Mass.--(BUSINESS WIRE)--Transcatheter heart valve company CardiAQ Valve Technologies (CVT), which is developing the world’s first self-conforming and self-anchoring technology for Transcatheter Mitral Valve Implantation (TMVI), announced today that it has closed a $6.5 million ‘Series A’ funding led by a group of private investors with proven expertise in the transcatheter heart valve space. The funding, which incorporates conversion of all previous debt, will be used to technically and clinically validate the CVT technology and is expected to carry the Company through initial first-in-man studies.